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Abstract 
Misexpression of germline genes like Cancer Testis (CT) genes, called a soma-to-
germline transformation, is a phenomenon linked to tumorigenesis. However, the 
mechanisms underlying this phenomenon are poorly understood. A soma-to-germline 
transformation in Caenorhabditis elegans occurs due to the loss function of the highly 
conserved DREAM (Dp, Retinoblastoma (Rb)-like, E2F, and MuvB) transcriptional 
repressor complex. In mammalian cells, the DREAM complex (Muvb core complex, 
E2F4/5, DP1/2, and p130/p107 proteins), as well as the Retinoblastoma protein (pRb), 
are implicated in transcriptional repression of cell cycle genes in quiescence or G0. We 
hypothesize that the expression of CT genes in malignant cells occurs because of the loss 
of activities of DREAM complex or pRb, similar to how the soma-to-germline 
transformation occurs in C. elegans. Thus, we expect that cancer cells that express CT 
genes will either fail to arrest in G0 or display defective repression of key cell cycle 
genes. To test sensitivity cells to arrest in response to limiting growth conditions, we did 
flow cytometry to measure the DNA content of 10 cell lines. We found that seven cell 
lines arrested in G0/G1, indicating that these cells have downregulated CT genes 
expression, and DREAM or Rb is involved in repressing cell cycle in G0/G1. This result 
also suggested that in the cells that did not arrest, both DREAM and Rb are inactive. 
Next, to test the mRNA expression of CT genes of all the cell lines, we did mRNA 
analysis of CT genes. We found that CT genes are expressed in proliferating cells of both 
cells that can arrest under limiting growth conditions and the cells that do not, indicating 
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we did not observe a difference in mRNA expression between cells that arrest and cells 
that do not. To test if CT misexpression is associated with dysfunction in either Rb or 
DREAM, we did further analyses to test early and late cell cycle genes expression in 
SW480, NCI-H1299, and 8MGBA, comparing the expression of cell cycle cells in 
proliferating cells to arrested cells in G0/G1. We found that mRNA expression of early 
cell cycle genes MCM5, ORC1, and CDC45 are downregulated, as expected since 
DREAM and Rb regulation of these genes overlap. However, DREAM solely regulates 
G2/M genes like CCNB2, PBK, and BUB1. We found that G2/M genes were not in 
significantly downregulated in NCI-H1299 and SW-480 cells, suggesting that DREAM is 
dysfunctional in these cell lines. As a secondary test of DREAM and Rb function, we 
performed luciferase reporter assays with promoters of DREAM and Rb target genes in 
SW480 and NCI-H1299 cell lines. Surprisingly, we observed that Rb is dysfunctional in 
SW480 cells. Together, these studies will facilitate future studies into the link between 
cell cycle regulation and CT upregulation in cancer cells.  
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1.1 Introduction 
Cancer is a very dynamic complex disease. Over time, it develops from 
accumulations of genetic and epigenetic alternations as a result of mutations that cause 
uncontrolled cell division [1]. There are estimated numbers that approximately 1 million 
new cancer incidences annually in males and more than 900,000 in females between 2010 
and 2020 in the U.S. The majority of cancer types expected to increase in males are 
melanoma, prostate, and kidney cancer. Moreover, breast, lung, and uterine cancer are the 
most cancer types expected to increase in females [2]. 
Despite the rapid advance in the fields of biological sciences in an understanding 
of molecular cancer genetics, how normal cells acquire the malignant characteristics is 
not completely understood. There are traits that normal cells acquire to transform into 
cancer are called "Hallmarks of Cancer" [3]. Each hallmark contributes to cancer and can 
help to understand tumor pathogenesis and the complexity of cancer. 
Normal cells have many regulators and pathways that control cell division and 
prevent DNA damage. Some of these regulators promote cancer development if they are 
inactivated. For example, one of the critical regulators is the Retinoblastoma (Rb) protein 
which is inactivated in many human cancerous [4]. The Rb family proteins including 
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Rb/p105, Rb2/p130, and p107 control cell cycle progression and DNA replication 
through interaction with E2F to regulate the gene expression of a set group of genes [5]. 
Both The retinoblastoma pRb and DREAM have similar functions in that they 
induce transcription repression in G0/G1 by interaction with E2F elements. DREAM has 
a distinct function from pRb/E2F that it regulates many of cell cycle genes involved in 
DNA replication, chromosome segregation, DNA repair, histone modification, and 
chromatin organization including BRCA1, BRCA2, FANCD1, FANCA, CDC6, CDK2, 
and EZH2 because it can bind to both E2F and CHR sites [6].  
The p53-p21-DREAM pathway controls the cell cycle through downregulation 
the expression of many genes that are involved in cell cycle progression. It regulates 
more than 250 genes that are associated with cell cycle progression. This pathway targets 
genes from the G1, G2, and M phase [7]. Thus, it controls all checkpoints, including G1, 
S, G2, and M. Defects in genes that regulate cell cycle cause aberrant checkpoint control 
that promotes aneuploidy and chromosomal instability in cancer cells [8]. 
Previous studies reported that Cancer/testis (CT) genes are ectopically activated in 
many human cancerous under pathogenesis conditions. CT genes have a pattern of 
expression that is restricted to normal and tumor cells [9]. Since then, many studies have 
emerged to address the factors or mechanisms that contribute to re-repression CT genes 
in human cancer cells. However, the mechanisms that drive the activation of CT genes in 
2 
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somatic cells still unknown. Therefore, we propose that the activation of CT genes may 
be a result of the dysfunction of both transcriptional repressors RB and DREAM in 
mammalian cells. 
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1.1.2 The six hallmarks of cancer cells 
Cancer cells display unique traits or hallmarks that promote uncontrolled 
proliferation and malignancy as compared to normal somatic cells. Six cancer hallmarks, 
in particular, have been defined. These include self-sufficiency in proliferation signals, 
inactivation of tumor suppressors, enabling of replicative unlimitedly, activation of 
invasion and metastasis, stimulating angiogenesis, and resistance to cell death [3]. 
Alterations of many functionally overlapping molecular pathways govern the prevalence 
of each cancer hallmark in a given tumor type. There is a need to identify the potential 
causes that drive these alternations in all types of cancers. Therefore, research into the 
molecular pathways that contribute to these six cancer hallmarks continues to drive the 
development of new methods to combat cancer. 
Regarding the first hallmark, genetic or epigenetic alternations in tumors enable 
them to require the ability to sustain signals that promote chronic division and 
proliferation [3] [10]. Many of genetic and epigenetic changes are oncogenic mutations 
that affect signaling pathways, leading in turn to an anti‐apoptotic potential, deregulated 
mitogenic, and increased motility in tumor cells [11]. For instance, increased pRb 
phosphorylation leads to loss of Rb function, and it occurs in most cancer types [12]. 
Oncogenic mutations cause upregulation of transcription of cyclin-dependent kinase 
(CDK) that mediate phosphorylation of pRb during the transition from G1 to S phase. It 
occurs in response to proliferative signals, that causes it to release of E2F, which 
promotes entry into S phase [13]. Inactivation of the tumor suppressor signaling 
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pathways leads to remove negative regulators of signaling that play an essential role in 
proliferation and progression in cancer cells [10]. 
Regarding the second hallmark, pRb and p53 functions are inactivated in most 
tumor cells and are a typical example of cancer cells evading tumor suppressor pathways 
[3]. These proteins have the role of suppressing and controlling cell growth and inducing 
senescence (cellular aging) and programmed cell death (PCD) [14]. The p53 gene 
regulate many functions of the cell cycle, including repairing damaged DNA, arresting 
growth, and apoptosis [15]. Gain- or loss-of-function in pRb or p53, which regulates 
proliferation, can trigger senescence, a normal process involving the irreversible arrest of 
normal cells [16] [17]. For instance, loss of function in p53 causes defects in cell cycle 
checkpoints and DNA damage repair, leading to chromosomal instability and increased 
mutation rates [18]. The majority of human cancer have mutated pRb or p53 genes 
because of the loss of functions of p53 and pRb pathways that promote tumorigenesis and 
tumor progression [19]. 
The third hallmark of tumor cells is their ability to resist cell death, or apoptosis 
[3]. Apoptosis is a tightly controlled mechanism involving energy-dependent cascades 
[20]. Apoptosis has two pathways: the intrinsic or mitochondrial pathway and the 
extrinsic pathway. The intrinsic signaling pathway involves intracellular signals that are 
regulated by the mitochondria [20]. In the latter case, the cell receives cell-death signals 
from outside itself, which induce cellular suicide [21]. The evading of apoptosis in cancer 
cells can occur by different mechanisms, such as the loss of function of the p53, 
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overexpression of survival signals for example Igf1/2 during the cell death pathway, and 
overexpression of antiapoptotic Bcl-2 proteins that regulate apoptosis by binding to 
proapoptotic triggering proteins such as Bak and Bax, thereby suppressing their functions 
[22]. In cancer cells, there is an imbalance between cell death and cell proliferation, and 
the cells that should undergo apoptosis did not receive apoptotic signals. Therefore, 
understanding apoptosis is essential because it can give us insight into the pathogenesis 
and design an effective treatment of cancer. 
 
The fourth hallmark of cancer cells is their capacity for replicative immortality 
[3]. The telomere, which is made by telomerase enzyme, is cap-like nucleoproteins found 
at the tips of chromosomes to protect them from fusion and stabilizes the chromosome 
and the DNA replication process in the eukaryotic cells [23] [24]. 
 
Normal human somatic cells pass through multiple cell divisions, then enter 
senescence and then eventually apoptosis. During multiple replication cycles, the 
telomeres shorten, and telomerase activity becomes repressed. However, in cancer cells, 
telomerase typically activated during immortalization [25]. Due to either genetic or 
epigenetic alterations, in malignant tumors, the telomerase lengthens; the tumor cells thus 
show high levels of telomerase activity during the process of immortalization, leading to 
chromosomal instability [26]. Telomere length besides telomerase activity play a crtical 
role in oncogenesis. Thus, it is important to focus on understanding the mechanisms that 
trigger the reactivation of telomerase in cancer cells, because it can help to discover 
promising biomarkers that can contribute to detect cancer at early stages [27]. 
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The fifth hallmark is the initiation of tumor angiogenesis processes, which is the 
secretion of angiogenic growth factor proteins by cancerous tumors that stimulate to form 
new blood and lymphatic vessels [3]. Cancer cells form new vascular network because of 
proliferation, and metastatic spread requires access to oxygen, nutrition, and removal of 
the waste products [28]. It allows cancer cells to leave the primary site and migrate 
through the bloodstream to invade secondary sites to form colonies, as well as to 
metastasize in the late stages of the disease [3]. Previous histological studies on human 
tumors have considered a link between p53 and angiogenesis. Tumors with mutated p53 
are significantly more vascularized and aggressive than those that have retained 
functional p53 [29]. The angiogenesis process is essential for cancer cells because it 
enables them to form vascular networks through the bloodstream from the primary site 
and migrate to settle a secondary site or metastasis site. Therefore, prevention of tumor 
angiogenesis processes can combat neoplastic growth at the primary site and prevent 
metastasis of tumor in late-stage, that will allow for treatment by therapeutics. 
 
The sixth hallmark is that tumor cells can penetrate surrounding tissues and 
metastasis. Metastasis is observed when malignant tumors migrate from the primary site 
by the bloodstream or lymph vessels, to form new tumors at other locations [3]. The 
tumor cells interact both cell-to-cell and within the extracellular matrix (ECM). The ECM 
contributes to changes in cell adhesion, thus providing a conducive environment in which 
the tumor can grow. The pRb protein can mediate these pathways and contribute to 
dissociating tumor cells from their original location [12]. Metastasis may occur due to 
defects in the epidermal growth factor receptor (EGFR), which regulates the cellular and 
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homeostatic proliferation of epithelial tissues in normal cells [30]. Analysis of EGFR 
expression levels in vitro shows that metastatic cells are highly expressive of EGFR when 
compared with non-metastatic cells in human colon cancer (HCC) [31]. Besides the focus 
on developments of methods to detect the tumor at an early stage. It is crucial to 
understand the mechanisms underlying the metastasis because once tumors spread and 
migrate from the original site, they can be incurable and fatal [32].  
 
The six cancer hallmarks that cancer cells are acquired to develop tumors are 
important to understand the pathogenetic mechanisms of a very complex disease such as 
cancer, and to support therapeutic strategies to fight this disease. They are including 
stimulating proliferative signaling, inactivating growth suppressors, enabling replicative 
unlimitedly, resisting apoptosis, inducing angiogenesis, enabling invasion, and metastasis 
[3]. 
 
pRb and p53 are significant players in cancer development. However, many 
questions remain as to how pRb and p53 regulate cell cycle genes, and how Rb and 
DREAM overlap different in their functions to repress cell cycle genes in G0, G1, S, G2 
and M phase. 
 
Since it is known that p53 acts as repressor and activator, how its functions can 
influence the p53-DREAM pathway is still not completely understood. Besides, the 
mechanism of repression cell cycle genes indirectly by the p35-DREAM pathway 
9 
remains unsolved issues, and it is a big challenge for scientists because it showed 
unexpected findings that are raising new questions. 
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1.1.3 Dysregulation of pRb is associated with tumor 
development 
pRb is the first known tumor suppressor that regulates cell cycle progression [50]. 
The Rb family consists of three homologs, pRb (RB1), p107 (RBL1), and p130 (RBL2), 
also known as pocket proteins [51]. The retinoblastoma protein inhibits gene transcription 
by activating the E2F-DP transcription factor at E2F sites to repress gene expression of 
genes required in transition from G1 to S phase leading to cell cycle arrest at early G1 
phase [52]. Genetic studies of knockout Rb genes show that they have many functions 
and participate in multiple cellular processes such as gene expression and regulation, 
cancer development, and cell cycle control [53]. The retinoblastoma tumor suppressor 
gene (RB) is inactivated in the most of human cancers due to direct mutation or deletion, 
such as small-cell lung carcinoma, and retinoblastoma, or indirectly by alterations of the 
activities of the upstream regulators [54].  
 
In tumor cells containing oncogenic mutations, the Rb pathway is disruption. 
Following mitogenic stimulation, P21/CDKN1A inactivate cell cycle by inhibiting 
cyclin-dependent kinases (CDKs) function that cause phosphorylate of the pocket 
proteins p107/p130 [55]. Phosphorylation of Rb proteins leads to release of E2F from 
inhibition and activate of the cell cycle genes that are required for S phase entry [52]. 
 
The pRb regulates cell division in the nucleus by preventing the progression of 
the cell cycle. In normal cells, Rb is found in non-phosphorylated status, and bound to 
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E2Fs in G0/G1 [52]. During the phosphorylation of Rb that occurs by cyclin D-CDK4 
and cyclin D-CDK6, it prevents Rb association with E2Fs. Thereby, it facilitates E2Fs to 
activate the transcription of genes that are essential for S phase entry [56]. Altered 
expression of cell cycle regulators, including cyclin D, CDK4, and their principal 
inhibitor p16, is very common in cancer cells. By the end of G1, binding cyclin proteins 
cause inactivation by cyclin cd complex. This inactivation causes pRb to release bound 
E2F transcription factors, which promote the expression of genes that are essential for 
cell progression from G1 to S phase [56]. Loss of functions of Rb is common in the 
majority of human cancers by different mechanisms. For instance, inactivation of Rb in 
human papillomavirus (HPV) is a result of E7 which is oncogenic protein that binds to 
Rb and inhibits its activity from repress damaged cells leading to cell proliferation [57].  
Overlapping activations of pRb/E2F and DREAM are required for cells to enter 
G0 or quiescence through indirectly repression by the p53-DREAM pathway. The 
pRb/E2F and DREAM complexes promote cell cycle arrest via CHR or E2F sites in 
G0/G1 phases. Rb and its related proteins p130 and p107 have a master function to 
repress gene transcription by binding to E2F sites and inhibit their activities during G1 to 
S phase transition [7].  
The pRb-related proteins p130/p107 become hypophosphorylated as a result of 
the expression of p21/CDKN1A that leads to gathering proteins that are involved in 
formation DREAM complex for repressing transcription through E2F or CHR promoter 
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sites. The p130/p107, E2F4, and E2F5 are bound via E2F cities during transcriptional 
repression of the cell cycle [50]. 
 
The p130/p107 are essential components of the DREAM complex that mediate 
gene repression [7]. Because of that, knockdown pocket proteins p107/p130 lead to a loss 
of DREAM function as a transcriptional repressor [58]. However, how pRB/E2F and 
DREAM complexes overlap functions to coordinate cell cycle checkpoints remains 
unclear. 
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1.1.4 DREAM complex pathway in repression cell cycle genes  
DREAM complex is a highly conversed protein that represses cell cycle genes 
during quiescence in mammalian cells [6]. It is composed of p107 or p130, E2F4-5/DP 
and MuvB core (figure 1) [58] [68]. It plays a critical role in the downregulation of cell 
cycle gene expression through quiescence and early G1 [69]. It binds to DNA promoters 
via the cell cycle genes homology region (CHR) or E2F sites through the cell cycle. It 
also binds CLE (CHR like element) and CDE (cell cycle-dependent element) sites on 
DNA. However, it cannot bind to DNA sites by CDE or CLE alone; it requires support by 
either CHR or E2F [70].  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1  DREAM complex components in mammalian cells. DREAM binds 
E2F/CHR or E2F/CLE, and CHR/CDE sites during G0/G1 to repress the transcription of 
the cell cycle genes in G0 and early G1 based on [7]. 
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Cell cycle genes have a repression mechanism indirectly through the p53-p21-
DREAM pathway. In G0/G1, cell cycle genes are repressed by the interaction of 
DREAM complex and RB-E2F through E2F sites on DNA [71]. In respond to DNA 
damage, p53 becomes activated, which leads to induce the expression of p21/CDKN1A. 
It produces p21 that form p21/CDKN1A that interacts with cyclin-dependent kinases 
(CDKs) and inhibits activity. It leads to phosphorylate the pRB-related proteins p107, and 
p130. As a result of that, p107 and p130 become hypophosphorylated and can form 
DREAM complex with other proteins to repress the transcription by binding DREAM to 
E2F or CHR sites [7]. In late G1, and early S phase, DREAM complex dissociates from 
repressive components E2F/pRB and p107and p130 and binds to transcriptional 
activators B-MYB to form B-MYB-MuvB complex that switch the repression to 
activation. 
In late S and early G2 phase, FoxM1 (Forkhead box M1) binds to the complex 
and form FOXM1-MMB complex. The B-MYB and FoxM1 coordinate gene expression 
of many cell cycle genes during S and G2/M phases [72]. The MuvB core comprises of 
LIN9, LIN37, LIN52, RBBP4 proteins, and LIN54, in contrast to the DREAM complex, 
it does not have the E2F, Rb, and DP proteins and only binds to CHR promoter sites [7]. 
MuvB interacts with BMYB and FOXM1 to regulate gene expression through S phase 
and G2/M [6]. Because MuvB based complex can change its formation, it binds to B-
MYB or FoxM1 and forms B-MYB-MuvB (MMB) that turns repression to activation 
when LIN54 binds to CHR site with peaks expression in G2/M phases [7].  
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p53-DREAM pathway is a critical pathway because it contributes to cell cycle 
arrest, and it represents a promising therapeutic target for cancer. Disruption of the p53-
DREAM pathway results in loss of checkpoint control. Importantly, many of the p35-
DREAM pathway genes are involved in many vital cellular processes such as 
chromosomal segregation. Hence, the deregulation of their expression contributes to 
aneuploidy and chromosomal instability in cancer cells. 
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1.1.5 Downregulation expression of cell cycle genes by p53 
p53 is a critical tumor suppressor that downregulates many cell cycle genes 
leading to cell cycle arrest or apoptosis [15] [59]. It is a transcriptional activator and 
repressor, as well [60]. The p53 gene is mutated in more than 50% of human tumors [61].  
Many target genes of p53 discovered that mediate its function as a tumor suppressor 
(Table 1.1) [69]. 
 
Mutations in p53 are oncogenic and contribute to neoplastic transformation [62] 
[63]. The activation of p53 is regulated by mouse double minute 2 homolog (MDM2). 
MDM2 is an important negative regulator of p53 that inhibits its activity, and it is 
overexpressed in sarcoma. Upon activation, the MDM2 gene interacts with p53 by 
directly binding to its transactivation domain and inhibits its transcriptional activity 
leading to ubiquitination degradation of p53 [64].  It downregulates many cell cycle 
genes from G1 through cytokinesis. It responds to stress signals in many ways by 
regulation cell cycle pathway, DNA repair, apoptosis, and senescence [65]. It stimulates 
many target genes that promote apoptosis, including, but not limited to, PIG3 (tumor 
protein p53 inducible protein 3), Bax (BCL2-associated X protein), and PUMA (p53 up-
regulated modulator of apoptosis) [66].  
 
The p53 gene has an indirect repression mechanism, which is regulated by the 
expression of some downstream effectors such as p21, CDN1A, miRNAs, and E2F7 [67]. 
Upon activation, p53 downregulates many cell cycle genes through the p53-DREAM 
17 
pathway (figure 2). DREAM and RB-E2F have overlapping functions, and they promote 
transcriptional repression and cell cycle arrest by p53. Activation of p53 leads to cell 
cycle arrest during G1 and G2/M checkpoints. It recruits the DREAM complex to 
downregulate the expression of a set range of essential of the cell cycle progression [7]. 
In response to DNA damage, p53 activates p21 that inhibits cell division-stimulating 
protein (cdk2) activity leading to indirect transcriptional repression and stop cell cycle 
progression and ultimately arrests the cell in G0/G1 [7].  
Figure 2 indirect repression of the expression of the cell cycle genes through p53-
p21-DREAM pathway. p53 activates p21 in response to DNA damage, which stops the 
cell cycle by inhibiting Cyclin CDK complexes based on [70].  
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E2F7 REV3L S100A2 TYMSOS FCHO2 TRIM32 PMAIP1 TSKU SPATA18 AMZ2 
SRA1 ISCU GRHL3 PANK1 TP53I3 CCDC90B PRKAB2 RNF19B FAM210B SERPINB5 
MAST4 MCC FDXR COL7A1 CDIP1 FAM212B IGDCC4 RETSAT EPHA2 RETSAT 
PSTPIP2 CPSF4 TSPAN11 CSNK1G1 ASTN2 TRIM35 KCTD1 IRF2BPL SEMA3B SCRIB 
DGKA WDR63 ANXA4 ATF3 CD82 HHAT USP15 CD82 FLRT2 BHLHE40 
CYFIP2 BLCAP BTG1 BLCAP SYTL1 KRT15 MICALL1 RRAD FAM84B SLC9A1 
FAM84B AKAP9 BCL6 ADIRF PPFIBP1 TXNIP ADIRF ITGA3 PPFIBP1 TXNIP 
HES1 HES1 DGKA PSTPIP2 CMBL WDR63 KRT15 ANXA4 FLRT2 IER5 
Table 1.1 Examples of P53 target genes 
19 
1.1.6 Aberrant expression of cancer/testis (CT) genes in somatic 
cells 
The processes that drive the evolution of germ cells and tumor cells share similar 
biological characteristics. Recognition of the biological features of the trophoblast cells 
tumor cells led to propose a hypothesis called the 'trophoblastic theory of cancer', which 
suggests that cancer cells emerge from germ cells that unable to continue migrating to the 
gonads during embryonic development [34]. Trophoblast cells are known as the cells that 
form the outside layer of the blastocyst to become the placenta in mammalian cells [35].  
Since then, many genes have been discovered that are expressed in germ cells, 
trophoblasts, and tumors, and these are known as cancer/testis (CT) genes [9]. CT genes 
encode immunogenic antigens called Cancer Testis Antigens (CTA). These antigens can 
evoke cellular and humoral immune responses in patients with cancer [36]. 
Because of the discovery of CT gene expression in many cancer cell types, one of the 
theories proposed that the ‘misexpression’ of germline genes in cancer cells is as a result 
of a silenced gametogenic program, it being abnormally activated in somatic cells. Thus, 
the activation of gametogenic program is one of the factors that drive tumorigenesis [37].  
 
It is during early embryonic development that the fate of all cells is determined. 
The cells become either non-reproductive somatic cells or germ cells that eventually form 
the germline that produces an organisms’ gametes, sperm, or eggs [38]. Germline genes 
are normally expressed in the male testis or female ovaries and placenta [39]. Somatic 
cells silence or turn off germline genes, but cancer cells often misexpress a class of 
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germline genes called CT genes. The expression of the germline in malignant cells is 
called the soma-to-germline transformation, a de-differentiation phenomenon observed in 
somatic cells in model organisms like Drosophila melanogaster and Caenorhabditis 
elegans [40]. Misexpression of germline genes appears to be linked to cancer initiation 
and progression in mammalian somatic cells. Aberrant expression of CT genes causes 
chromosome missegregation and aneuploidy in cancer cells [36]. Loss of CT genes 
repression in tumor cells is a hallmark of cancer disease. Thus, understanding genetic and 
epigenetic alterations in tumor cells that occur as a result of misexpression of CT is 
important, because it can help to understand the mechanisms that contribute to inhibit 
expression of the CT genes in somatic cells to protect their fates during development 
[40]. 
 
CT genes are ectopically expressed in many types of cancer cells, and classified 
into two groups, depending on chromosome localization [36]. The first group is CT genes 
encoded by X chromosome genes; 10% of these genes are expressed in tumor cells and 
contribute to tumor evolution [41]. The second group comprises CT genes that are 
encoded by non-X chromosome genes and found on autosomal chromosomes expressed 
during meiosis [42]. The molecular and physical functions of most CT genes remain 
unclear [36]. Because CT genes are ectopically expressed in many human cancer types, it 
is necessary to understand the mechanisms that drive their activation in tumors. 
CT genes are frequently expressed in tumor types such as bladder cancer, lung 
carcinomas, hepatocellular carcinomas, melanomas, and ovarian cancer [43]. Although 
some cancer types show poorly expressed CT genes, such as glioblastoma and clear cell 
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renal cell carcinoma (CCRCC), melanomas, and lung carcinomas show abundant 
overexpression of CT genes [44]. The melanoma antigen gene (MAGE) family is 
frequently overexpressed in lung adenocarcinomas, while semenogelin 1 (SEMG1) is 
frequently overexpressed in colon cancer. Basal cell breast cancer shows enriched 
expression of melanoma-associated antigen 3 (MAGEA3), actin-like 8 (ACTL8), and 
chromosome X open reading frame 6 (CXorf6). Magnoid lung adenocarcinomas show 
overexpressed MAGEA1, MAGEA3, MAGEA4, MAGEA12, and CSAG1[44]. 
Currently, the mechanism underlying how each CT gene is misexpressed in such a wide 
variety of cancer cell types remains unknown. 
 
CT proteins evoke an immune response in cancer cells and have an expression 
pattern that is specifically associated with tumor cells and not found in most normal 
tissues. This makes them unique targets for immunotherapy in cancer treatment [45]. 
Despite the fact that understanding the expression pattern of these genes would help to 
identify driver genes in cancer, few studies have investigated why and how the oncogenic 
mechanisms of CT gene expression impact human somatic tissues.  
 
Research on CT genes presents a challenge for scientists. Firstly, most studies that 
have analyzed the expression of CT genes have involved just a small number of samples 
[46]. Secondly, many CT genes remain uninvestigated in terms of how they abnormally 
reactivated and whether their expression can trigger, or is associated with, tumor 
progression. Although the mechanisms that drive CT co-expression in somatic and cancer 
cells remain poorly understood, ectopic expression of CT genes is known to reflect a ‘cell 
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identity crisis. Normal cells are able to change their identity under pathological 
conditions. Most cancer cells arise from the epithelial cells that form the skin. In breast 
cancer, for instance, cells change their epithelial identity and acquire invasive and 
metastatic characteristics – a process which is known as epithelial-mesenchymal 
transition (EMT) [47]. 
 
In the C. elegans model system, a soma-to-germline transformation occurs as a 
result of loss-of-function mutations in a homolog of the tumor-suppressor pRb, called lin-
35. The loss-of-function of lin-35 leads to misexpression of the germline-specific 
gene pgl-1 [48]. Similarly, the mechanism that drives soma-to-germline transformation 
in C. elegans might also contribute to the reactivation of CT genes in mammalian somatic 
cells, though a variety of factors may influence this transformation in human somatic 
cells [49]. Thus, this study hypothesizes that ectopic expression of CT genes in human 
somatic tissues is associated with dysfunction of both the transcriptional repressors 
DREAM and RB-E2F complexes by oncoproteins. 
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1.1.7 Study hypothesis 
In our project, we are addressing the factors that drive the soma-to-germline 
transformation that occurs in cancer cells in mammalians. In particular, we focus on how 
the loss of both transcriptional suppressors can promote ectopic expression of 
Cancer/testis genes (CT) in human cancers. Our hypothesis suggests that cancer cell lines 
that have Rb and DREAM complex that are functioning normally or that have either 
DREAM or Rb is dysfunction can exit cell cycle under limiting condition (figure 3). 
However, cancer cells that are lacking both DREAM complex and Rb can not exit cell 
cycle therefore they can proliferate normally under limiting growth conditions (figure 1A 
and1B). Thus, we propose that misexpression of CT genes in tumor cells is associated 
with loss of functions of both DREAM and Rb. 
 
First, we used Flow cytometry to measure the DNA content of 10 cell lines. We 
found that the majority of the cell lines, a total of seven of the cell lines arrested in 
G0/G1, under limiting growth conditions. A total of three of the cell lines did not arrest in 
G0/G1. Next, we analyzed the mRNA expression of many CT genes in proliferating cells 
of all the cell lines. However, we did not observe specific gene expression pattern 
between all the cell lines. Then, we analyzed the mRNA expression of Rb and DREAM 
G0/G1 and G2/M target genes in 8MGBA, NCI-H1299, SW480 cell lines to test if the 
misexpression of the CT genes is associated with loss of functions of DREAM or Rb. The 
mRNA expression results suggest that DREAM and Rb G0/G1 target genes are still 
down-regulated in serum-starved cells as compared to proliferating cells, however low 
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fold-change levels might indicate loss of function of either DREAM or Rb. Analysis of 
G2/M late cell gene expression in serum starved cells suggest that DREAM is 
dysfunctional in SW480 and H1299 cell lines. However, luciferase reporter analyses 
revealed that Rb is dysfunctional in SW480 cells. Together, these studies will facilitate 
future studies into the link between cell cycle regulation and CT upregulation in cancer 
cells. 
Figure 3  Models show how soma-to-germline transformation can occur in human 
cancer cells as a result of dysfunction of both DREAM complex and Rb. 
(A) A model of DREAM and Rb activity in human cancer cells, both DREAM and
Rb arrest cell cycle in G0/G1, and they can arrest cell cycle even if one of them is
dysfunction, however if they both are dysfunction they cannot arrest cell cycle
expression in response to limiting growth condition.
(B) A model describes how soma-to-germline genes transformation can occur in
human cancer cells.
A B 
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1.2 Methods 
1.2.1 Cell culture 
The human ovarian carcinoma OVCAR3 cells, SKOV3 human ovarian cancer 
cells, ES-2 ovarian cells, lung cancer cell line NCI-H1299, human ovarian cancer cells 
OVCAR5, and human ovarian cancer cells OVCAR10 were cultured in RPMI medium 
supplemented with 10 % fetal bovine serum (FBS). The SW480, MDA-MB-231, T98G, 
and 8MGBA cells were cultured in DMEM medium with 1% Glutamax and 10% FBS. 
The cells were plated in 6-well plates (250,000 cells) for each well. The cells were 
separated into three groups; proliferated cells were cultured for 24 hours to reach 80-90% 
confluency. Serum starvation added to the cells for 48 hours. After serum starvation, 
serum release added to the cells for 24 hours. Cells were washed once with PBS before 
added serum starvation or serum release. At 24,48 h, adherent cells were detached using 
trypsin. The cells were starved by 2 mL of serum starvation containing RPMI medium 
supplemented with 1% penicillin/streptomycin or DMEM with 1% 
penicillin/streptomycin and 1% Glutamax for 48 hours, and re-stimulated by added 2mL 
of serum released containing either DMEM or RPMI medium with 20% fetal bovine 
serum (FBS), 1% Glutamax and 1% penicillin/streptomycin for 24 hours and seeded at 
different times. Proliferating cells were seeded after 24 hours, serum-starved cells after 
48 hours, and serum released after 24 hours. All the cell lines were maintained at 37°C 
and 5% CO2. 
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1.2.2 Flow Cytometry 
To measure DNA content, all cell lines were plated in 6 well-plates (125,000 cells 
per well). They were grown in DMEM or RPMI medium for 24 hours. The cells were 
grown under serum starvation for 48 hours, and serum released for 24 hours after the 
serum starvation. The cells were trypsinized and stored in 500 μl of 70% Ethanol at -20 
°C overnight. Then, they were centrifuged at 4,000 rpm for 2 minutes at 4 °C. Next, they 
were resuspended in PBS that contains 0.25% Triton X-100. They were incubated on ice 
for 15 minutes and spun for 2 minutes at 4,000 rpm at 4 °C. They were resuspended in 
500μl PBS, 0.5μl of 10μg/mL Rnase A, and 10μl of 1 mg/mL Propidium Iodide (PI). 
Finally, they were transferred to the FACS tubes and stored for 30 minutes at room 
temperature before analyzed by Flow cytometry.  
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1.2.3 RNA extraction 
Isolation of total RNA with 500 mL of TRIZOL reagent and incubated overnight. 
Chloroform was added and transferred to a phase-lock tube and mixed. Then, it was 
incubated at room temperature for 10 minutes. The cells were centrifuged at 4 °C for 15 
minutes at 12,000 RCF. Next, the top aqueous layer was transferred to RNase free tube. 
Isopropanol was added and mixed and incubated at room temperature for 5 minutes. 
Then, the tubes were centrifuged at 4 °C. for 8 minutes at 12,000 RCF. The liquid was 
removed, and Ethanol/Nuclease-free water was added and centrifuged for 5 minutes at 
12,000 RCF. The liquid was removed from the tubes and centrifuged for 1 minute at 
12,000 RCF. The liquid was removed, and the tubes left open to dry by air for less than 4 
minutes. Lastly, Nuclease-free water was added and stored at -70 °C overnight. 
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1.2.4 Reverse Transcription 
The concentration of RNA was between 200-500ng, and RNase-free water total 8 µL. We 
made the first DNase l treatment master mix a total of 2µL per sample. The first master 
mix for RNA 500ng concentration was 1 µL of 10x DNase buffer, 0.25 µL of DNase I, 
and 0.75µL of RNase-free water per sample. The mix was added to each sample (2µL per 
sample). The tubes were incubated for 15 minutes at room temperature. Next, mM EDTA 
was added to the tubes (1µL per sample). The tubes incubated for 10 minutes at 65°C. 
The tubes were then transferred to an ice bath. We prepared RT-PCR master mix that 
contains of 10x RT buffer (0.2 µL), 25xdNTP Mix (100 mM) (0.8 µL), 10x RT Random 
Primers (0.2 µL), MultiScribe RTase (1 µL), and Nuclease-free water (3.2 µL) the total 
volume reaction was 9 µL per sample. A total of 9 µL of the mix was added to each 
sample and mixed and centrifuged. The samples ran on ABI simpliAmp cycler. The 
samples were diluted 1:2.5 or 1:5 per 500ng RNA amount and the ddH2O was 30 µL or 8 
µL after the dilution they were transferred to a fresh 1.5 mL tube. 
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1.2.5 Quantitative PCR 
We made a dilution with ddH2O for each Cancer/Testis gene (CT) that we used before 
making the primers. Next, we made a master mix reaction that contains 5 µL of 2x SYBR 
Green (ABI), 0.5 µL of 10µM Forward primer, 05 µL of 10µM Reverse primer, 2.0 µL 
of ddH2O per sample. The total volume was 8 µL per well. The plate was centrifuged at 
1500 rpm for 2 minutes and added to the qPCR machine and ran on ABI QuantStudio 3. 
 
30 
1.2.6 Transfection and luciferase assays 
To test promoter activities of DREAM with luciferase reporter assays, H1299, SW480 
cell lines were cultured in RPMI medium supplemented with 10 % fetal bovine serum 
(FBS) or DMEM medium with 1% Glutamax and 10% FBS. SW480-NCI-H1299 cells 
were plated in 24 well-plates (25000 cells per well) and incubate for 24 hours. Each well 
was washed with 0.5 mL PBS. The medium was replaced with serum-free media 
containing RPMI medium supplemented with 1% penicillin/streptomycin or DMEM with 
1% penicillin/streptomycin and 1% Glutamax for 24 hours followed by transfected.  
For transfection, Lipofectamine 3000 reagent mixes were made that contain: first mix 25 
µL of serum-free media, 50ng pGL4.70 Renilla, and 200ng pGL4.10 reporter, and 0.5 of 
µL P3000 reagent per well. The second mix was 25 µL of serum-free media, and 1 µL of 
Lipofectamine 3000 regent. The second mix was added to all the tubes of the first mix. 
The tubes were incubated at room temperature for 15 minutes. Next, 50 µL of the mix 
was added to each well and incubated for 48 hours. The reporters are Bub1 (WT), Bub1 
(CHR), ORC1(WT), and ORC1(E2F). After 48 hours, the wells were washed with 0.5 
mL PBS, and then 100 µL 1x Passive lysis buffer (PLB) was added to each well. The 
wells were incubated and shacked for 15 minutes. Next, 20 µL of lysate was transferred 
into a white 96-well plate, first: 20 µL of Luciferase Assay regent II (Luc) was added to 
each well, the reading for the plate was done by using Tecan Spark-Luciferase program, 
second 20 µL of Stop and Glo (S&G) was added to each well and the reading for the 
plate was done by using Tecan Spark (Renilla program).  
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1.3 Results 
 
1.3.1 Majority of human cancer cell lines tested arrest their cell 
cycle in growth-limiting conditions  
We are interested in understanding the key factors that drive CT genes activation 
in malignant cells. We hypothesize that loss-of-function of both cell cycle transcriptional 
repressor factors DREAM and Rb causes insensitivity to growth-limiting conditions. 
Therefore, we first aimed to identify human cancer cell lines that arrest versus cell lines 
that fail to arrest in limiting growth conditions, which would indicate that cell lines that 
loss of both DREAM and Rb functions cannot arrest in G0/G1. 
 
To categorize the response of human cancer cell lines to growth-limiting 
conditions, we measured the DNA content of the proliferated and serum-starved and 
serum released cells among ten cell lines. Using Propidium Iodide staining and flow 
cytometry, the DNA content of serum-starved cells was compared to normally 
proliferating and serum released cells. Serum starved cells were incubated in serum-free 
media for 48 hours, and serum released cells were serum-starved for 48 hours and then 
re-stimulated with media containing serum for 24 hours. We tested ten of human cancer 
cell lines, including breast cancer cell line (MDA-MB-231), human ovarian cancer cell 
line (ES-2), human ovarian carcinoma cell line (OVCAR-3) , ovarian cancer cell line 
(OVCAR-5), glioblastoma cell line (T98G), glioblastoma cell line (8MGBA), colon 
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adenocarcinoma cell line (SW480), lung cancer cell line (NCI-H1299), ovarian cancer 
cell line (SKOV3), and ovarian cancer cell line (OVCAR-10).  
To assess whether cells were sensitive to serum starvation, we measured the 
percentages of total cells in G1/S (2n) and G2/M (4n) in serum-starved cells compared to 
normal proliferating cells (figure 4A and 4B), (figure 5A and 5B), (figure 6A and 6B), 
and (figure 7A and 7B). We found that 7 out of 10 cell lines were sensitive to growth-
limiting conditions, indicating that they arrested in G0/G1. NC1-H1299 cells in G1/S 
increased from 55.65% to 89.70% in response to growth-limiting conditions, with a 
corresponding G2/M decrease from 29.30% to 4% (figure 4B). OVCAR-5 cells in G1/S 
increased from 65.57% to 83.87% in response to growth-limiting conditions, with a 
corresponding G2/M decrease from 20.51% to 8.13% (figure 4B). SW480 cells in G1/S 
increased from 65.57% to 74% in response to growth-limiting conditions, with a 
corresponding G2/M decrease from 18.49%% to 8.01% (figure 4B). MDA-MB-231 cells 
in G1/S increased from 63.30% to 81.80% in response to growth-limiting conditions, 
with a corresponding G2/M decrease from 25.40% to 13.30% (figure 5B). SKOV-3 cells 
in G1/S increased from 52.67% to 76.73% in response to growth-limiting conditions, 
with a corresponding G2/M decrease from 28% to 14.57% (figure 5B). 8MGBA cells in 
G1/S increased from 64.50% to 84.30% in response to growth-limiting conditions, with a 
corresponding G2/M decrease from 22.53% to 9.97% (figure 5B). T98G cells in G1/S 
increased from 44.33% to 71.30% in response to growth-limiting conditions, with a 
corresponding G2/M decrease from 15.97% to 8.93% (figure 6B). These results indicate 
that NC1-H1299, OVCAR-5, SW480, MDA-MB-231, SKOV-3, 8MGBA, and T98G cell 
line arrested in G0/G1 in limiting growth conditions.  
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In contrast, of the ten cell types, three cell lines were insensitive to growth 
conditions. ES-2 cells in G1/S and G2/M were 52-57% and 33-35% in all conditions 
(Figure 7B). OVCAR-3 cells in G1/S were 60-67%, and G2/M were 18-25% in all 
conditions (Figure 7B). OVCAR-10 cells in G1/S were 51-52%, and in G2/M, they were 
26% in all conditions (Figure 7B). These results indicate that ES-2, OVCAR-3, and 
OVCAR-10 did not arrest in G0/G1 in limiting growth conditions. 
 
In addition, we tested whether the repression of cell cycle genes during 
quiescence can be rescued by re-stimulation after serum starvation in OVCAR-5 cells 
that arrested in G0/G1. As expected, the results displayed an increase in total cells in 
G1/S and G2/M upon re-stimulation (figure 4A). Upon re-stimulation, the cells re-entered 
the cell cycle and proliferated normally in G1/S and G2/M and show peaks in G1 and 
G2/M. The cell percentage in G0/G1 is 65.57% and 20.51% in G2/M in proliferated cells. 
While it is 83.87% in G0/G1 and 8.13 in G2/M. However, it is 60.62% in G0/G1 and 
26.37% in G2/M in released cells (figure 4B).  
 
In total, 7 of cell lines arrested in response to serum starvation, including NC1-
H1299, OVCAR-5, SW480, MDA-MB-231, SKOV-3, 8MGBA, and T98G (figure 4A 
and 4B), (figure 5A and 5B) and (figure 6A and 6B). Three of the cell lines did not 
respond to serum starvation, including ES-2, OVCAR-3, and OVCAR-10 (figure 7A and 
7B).  
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Taking together, flow cytometry results revealed that the percentages of cells in 
G0/G1 and G2/M phases of the cell cycle significantly change in both proliferating and 
serum-starved cells in NC1-H1299, OVCAR-5, SW480, MDA-MB-231, SKOV-3, 
8MGBA, and T98G cell lines because of the cell arrested in G0/G1, and decreased in 
G2/M after serum starvation compared with proliferating cells. These cell lines that might 
have Rb or DREAM function correctly, are likely to be arrested in G0/G1 under growth-
limiting conditions. 
 
However, ES-2, OVCAR-3, and OVCAR-10 cell lines proliferated normally in 
G1, S, and G2/M even after serum starvation, and it might be as a result of loss activities 
of both DREAM complex and Rb that hinder cell cycle arrest following limiting growth 
conditions. These cell lines might lack both Rb and DREAM complex. Because of that, 
they are unable to exit the cell cycle. So, they proliferate normally.  
Thus, we are more interested in the cell lines that are arrested in G0/G1 (NC1-H1299, 
OVCAR-5, SW480, MDA-MB-231, SKOV-3, 8MGBA, and T98G to test how DREAM 
or Rb arrest cell cycle genes in G0/G1 in response to limiting growth conditions and 
whether one of them is dysfunctional in these cell lines. 
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(A) In response to serum starvation, H1299, SW480, and OVCAR5 cell lines showed 
only one peak in G0/G1 phase indicating that they arrested in G0/G1. 
(B)  The total percentage of the cells of H1299, SW480, and OVCAR-5 cell lines are 
increased in G0/G1 phase and significantly decreased in G2/M phase in H1299, 
and OVCAR-5 after serum starvation for 48 hours. 
 
 
Figure 4 DNA content of the proliferating, serum-starved, and serum released cells 
of NCI-H1299, SW480, and OVCAR5 cell lines as measured by flow cytometry. 
A B 
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Figure 5 DNA content of the proliferating, serum-starved, and serum released cells 
of MDA-MB-231, SKOV3, and 8MGBA cell lines as measured by flow cytometry. 
(A) In response to serum starvation, MDA-MB231, SKOV3, and 8MGBA cell lines 
show only one peak in G0/G1 phase indicating that they arrested in G0/G1. 
(B)  The total percentage of the cells of MDA-MB231, SKOV3, and 8MGBA cell 
lines are increased in G0/G1 phase and significantly decreased in G2/M phase 
after serum starvation for 48 hours. 
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Figure 6 DNA content of the of the proliferating, serum-starved, and serum released 
cells T98G cell line as measured by flow cytometry. 
(A) In response to serum starvation, T98G cell line showed only one peak in G0/G1 
phase indicating that it arrested in G0/G1. 
(B)  The total percentage of the cells of T98G cell line are increased in G0/G1 and 
significantly decreased in G2/M phase after serum starvation for 48 hours. 
 
 
38 
 
Figure 7 DNA content of the of the proliferating, serum-starved, and serum released 
cells of ES-2, OVCAR-3, and OVCAR-10 cell lines as measured by flow cytometry. 
(A)  ES-2, OVCAR-3, OVCAR-10 cell lines were insensitive to limiting growth 
conditions, and they show two peaks after serum starvation for 48 hours in G1/S 
and G2/M after serum starvation for 48 hours. 
(B) The total percentage of the starved cells of ES-2, OVCAR-3, and OVCAR-10 did 
not significantly change in compared with proliferating and serum starved cells 
indicating that ES-2, OVCAR-3, and OVCAR-10 did not arrest in G0/G1 in 
limiting growth conditions. 
A B 
39 
1.3.2 Exploring a potential relationship between CT genes 
expression and loss of DREAM and Rb function 
If CT gene misexpression is linked to loss of DREAM and Rb function, then we 
expect that CT gene expression would be increased in cancer cells that are insensitive to 
serum starvation as compared to cells that arrest in growth-limiting conditions. We tested 
the mRNA expression of 12 known CT genes among ten cancer cell lines using reverse 
transcriptase quantitative PCR (RT-qPCR). Representative CT genes tested include 
MAGEA4, TTK, SSX2, LIN28B, PIWIL, CTAGE2, SKA3, MAGEA12, MAGEA3, 
MAGEA6, YBX2, and KCTD19 (Table 1.2). 
CT genes are expressed in some human cancer cell lines that cannot arrest cells 
cycle in response to limiting growth conditions and proliferated normally in G1/S and 
G2/M. For example, MDA-MB3 cells expressed TTK and CTAGE2 genes (figure 8). 
OVCAR3 proliferated cells expressed TTK, SSX2, LIN28B, PIWIL, SKA3, YBX2, and 
CTAG2 genes (Figure 8) and (Figure 9). OVCAR10 cells expressed TTK, SSX2, and 
LIN28B (Figure 8). ES-2 expressed TTK and CTAG2 genes (Figure 8). 
In addition, CT genes are expressed in some human cancer cell lines that can 
arrest in G0/G1 under limiting growth conditions. For instance, NCI-H1299 cells 
expressed MAGE4, TTK, and LIN28B genes (figure 8). SW480 cells expressed TTK, 
PIWIL, SKA3, YBX2, and KCTD19 genes (figure 8) and (figure 9). OVCAR5 and 
SKOV3 cells expressed TTK and CTAG2 genes (figure 8). 8MGBA cells expressed 
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many CT genes such as TTK, SSX2, CTAG2, SKA3, MAGEA12, MAGEA3, MAGEA6, 
and KCTD19 (figure 8) and (figure 9). Finally, T98G expressed TTK and SKA3 genes 
(figure 8) and (figure 9). 
 
Taking together, we did not find differences between two mRNA expression 
between the two groups. There are some cell lines that share similar CT genes expression 
patterns. For instance, TTK genes are expressed in all the cell lines that we tested. We 
discriminated between these two groups and select only cells that arrested in G0/G1 in 
limiting growth conditions. Because we did not observe differences of CT gene 
expression between cells that can arrest and cells that cannot. We next asked if 
misexpression of CT genes might be associated with dysfunction in either or both Rb or 
DREAM. 
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Figure 8 mRNA expression of CT genes in proliferation cells of H1299, SW480, 
OVCAR-5, SKOV3, 8MGBA, T98G, MDA-MB-231, OVCAR-3, OVCAR-10, 
and ES-2 cell lines was analyzed by qPCR. 
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Figure 9 mRNA expression of CT genes in proliferation cells of SW480, 8MGBA, 
T98G, and OVCAR-3 cell lines was analyzed by qPCR. 
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ACRV1 ACTL9 ASZ1 BAGE2 BEND2 C17ORF64 C8ORF74 CABP2 CABYR CAPZA3 
CAGE1 CAPZA3 CCDC155 CATSPER4 CCL27 CTAG1B DAZ1 DBX1 DCAF8L1 DDI1 
DEFB112 DMRT1 DNAJB3 DPEP3 DPPA3 DSCR4 DUSP21 ENDOV EPPIN ERICH6 
EXD1 FABP12 FAM187B FAM209A FAM221B FAM46D FAM71E1 FAM9C FATE1 FBXO47 
FKBP6 FNDC8 GAGE12D GAGE12J GGN GJA8 GOT1L1 GPR32 GSTA5 GTSF1L 
H1FNT HDGFL1 HIST1H2BA HIST1H2BB HIST1H4F HSFX2 HYPM IGLL1 IL31 IQCF6 
IZUMO1 IZUMO2 KCNA10 KCNU1 KCNV2 KIF24 KLHL10 KRT26 KRT33A LCA5L 
LCE2D LCE3C LELP1 LIN28B LRRC52 MAEL MAGEA1 MAGEA12 MAGEA2 MAGEA3 
MAGEA4 MAGEA6 MAGEA8 MAGEA9B MARCH11 MMP20 NANOS2 NBPF6 ODF1 ODF4 
OPN1LW OPN5 OR10J1 OR13D1 OR13G1 OR14J1 OR1C1 OR1G1 OR1K1 OR1N1 
OR2A4 OR2D2 OR2F1 OR2G6 OR2K2 OR2W5 OR4D1 OR4E2 OR52D1 OR52E4 
OR56A3 OR5B2 OR5B21 OR5C1 OR5H6 OR5M11 OR6C2 OR6F1 OR7E24 OR8A1 
OR8B2 OR8B3 OR8D1 OTOP2 PAPOLB PCDHA1 PCDHA13 PDCL2 PDILT PDZD9 
PFN4 PGK2 PHF7 PIWIL3 POM121L2 POTEA POTEG POU5F2 PP2D1 PPEF2 
PRAME PRAMEF1 PRKACG PRM1 PRM2 PRPS1L1 PRR23A PRR23B PRSS37 PRSS41 
PSG11 PSG3 PSKH2 PSMA8 PTF1A R3HDML RAD51AP2 RBMXL2 RBPJL RGSL1 
RIMBP3 RIMBP3C RNASE8 RNF113B RNF133 RNF148 ROPN1 ROPN1B S100A7L2 SAGE1 
SCN10A SEL1L2 SHCBP1L SKA3 SLC25A2 SLC25A52 SLCO6A1 SLFNL1 SMC1B SMCP 
SOX30 SPA17 SPACA3 SPATA12 SPATA16 SPATA17 SPATA31D4 SPATA33 SPATA8 SPINT3 
SPRR4 SSMEM1 SSX1 SSX2 SUN3 SUN5 SYCE1L SYCN SYCP3 SYNGR4 
TAS2R1 TCEB3C TCP11 TDRD12 TEKT5 TEX101 TEX13B TEX19 TEX33 TEX35 
TEX38 TEX43 TMCO2 TP53TG3B TPPP2 TPTE TRIM48 TSPAN16 TXNDC2 USP29 
WBSCR28 WDR87 WFDC10A WFDC6 YBX2 ZAR1L ZC2HC1B ZDHHC19 ZNF645 ZSWIM2 
Table 1.2 Examples of cancer/testis genes (CT) 
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1.3.3 Early cell cycle genes are primarily repressed by both 
DREAM and Rb 
To test whether the DREAM complex or Rb are inactive in the cancer cell lines, 
we selected for further analyses SW480, NCI-H1299, and 8MGBA cells. We tested the 
mRNA expression of DREAM and Rb target genes in quiescent cells (serum-starved) and 
proliferated cells (serum-released) in SW480, NCI-H1299, and 8MGBA cell lines (Table 
1.3). Our hypothesis suggests that cell lines that cannot arrest are dysfunctional in both 
Rb and DREAM. However, cell lines that can arrest may be dysfunctional in either Rb or 
DREAM. Thus, we expect that either DREAM Complex or Rb work to repress CT genes 
in G0/G1 in the serum-starved cells in SW480, NCI-H1299, and 8MGBA starved cells. 
Therefore, one of them is broken. 
We tested early cell cycle genes (G1/S), and late cell cycle genes (G2/M) using 
RT-qPCR analysis on serum-starved and serum released human cancer cell lines. We 
selected SW480, H1299, and 8MGBA cell lines. 
To test the DREAM or Rb regulation of early cycle genes, we assessed expression 
levels of MCM5, ORC1, and CDC45 in quiescent cells (serum-starved) compared to 
proliferating cells (serum released). MCM5 has significantly downregulated in SW480 
serum-starved cells compared with proliferating cells with 12-fold change, suggesting 
that MCM5 gene is repressed by DREAM and Rb complexes in G0/G1 (figure 10). 
MCM5 is also downregulated in H1299 serum-starved cells with 3.8-fold repression and 
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8MGBA with 2.7-fold repression (figure 10). However, the repression in H1299 and 
8MGBA cell lines is not significant. Similarly, ORC1 is also significant downregulated in 
SW480 serum-starved cells compared with proliferating cells with the 7.5-fold change, 
and it is downregulated in H1299 starved- cells with 2.2 fold change compared to 
proliferated cells. It is also downregulated in 8MGBA with 2.4 fold change (figure 10).  
The expression of the CDC45 gene is lowly expressed in SW480 starved-cells with 3.6 
compared to proliferating cells (figure 10). In addition, it is lowly expressed in H1299 
serum-starved cells with a 6.7-fold change and downregulated in serum-starved 8MGBA 
with a 3.4-fold change (figure 10).  
 
Taken together, these results testing early cell cycle genes in NCI-H1299 and 
SW480 and 8MGBA cell lines suggests that either DREAM or Rb are functional. 
However, the lower fold change observed in NCI-H1299 and 8MGBA serum-starved 
cells as compared to proliferating cells suggest that 1 of the factors may be dysfunctional.  
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Figure 10 mRNA expression of early cell cycle genes (MCM5, ORC1, and CDC45) 
in the proliferated cells (yellow) and the quiescent cells (gray) in 8MGBA, H1299, 
SW480 cell lines was measured by qPCR and normalized to U6 expression. The 
mRNA expression results suggest that DREAM and Rb G0/G1 target genes are still 
down-regulated in serum-starved cells as compared to proliferating cells. 
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1.3.4 Late cell cycle genes are primarily repressed by DREAM 
Since the only DREAM represses late cell cycle genes, we assess expression 
levels of CCNB2, PBK, and BUB1 in quiescent cells (serum-starved) and proliferating 
cells (serum released). The expression of CCNB2 gene is downregulated in SW480 cells 
with 1.7 fold changes and NCI-H1299 with 1.3 fold changes and 8MGBA starved cells 
with 4 fold changes (figure 11). The expression of the PBK gene is partially repressed in 
SW480 cells with 2 fold change, and it is lowly expressed in H1299 quiescent cells with 
3.9 fold change, and in 8MGBA starved cells with 5.8 fold change (figure 11). The 
expression of the BUB1 gene is substantially impaired in SW480 serum-starved cells 
with 1 fold change (figure 11). It is partially downregulated in H1299 quiescent cells with 
fold change 4.9 (Figure 11), and it is downregulated in 8MGBA with fold change 5.9 
(figure 11) 
Taken together, these results testing late cell cycle genes in NCI-H1299 and 
SW480 and 8MGBA cell lines suggest that DREAM may be dysfunctional in NCI-1299 
and SW490, but the results are ambiguous. 
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Figure 11 mRNA expression of late cell cycle genes (CCNB2, PBK, and 
BUB1) in the proliferated cells (blue) and the quiescent cells (gray) in 
8MGBA, H1299, SW480 cell lines was measured by qPCR and normalized 
to U6 expression. Analysis of G2/M late cell cycle genes expression in serum 
starved cells suggest that DREAM is dysfunctional in SW480 and H1299 cell 
lines. 
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Gene name 
Litovchick 
2007 
DREAM 
Chicas 2010 
 
RB 
ANLN (Anilin) 
AURKA (AIK-1) 
AURKB (AIM-1) 
BIRC5 (Survivin) 
BRCA1  
BUB1  
BUB1B (BUBR1) 
CCNA1  
CCNA2  
CCNB1  
CCNB2  
CDC20  
CDC25A  
CDC25B  
CDC25C  
CDC45  
CDC6  
CDK1 (CDC2) 
CENPA  
CENPE  
+ + 
+ + 
+ - 
+ - 
+ + 
+ - 
+ - 
+ - 
+ - 
+ - 
+ - 
+ - 
+ + 
+ - 
+ - 
+ + 
+ + 
+ + 
+ - 
+ + 
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CENPF  
CHAF1B  
CHEK1 (CHK1) 
CIT  
CKS1B (CKS1) 
CKS2  
DCK  
DDX11 (CHLR1) 
DHFR  
DLGAP5  
E2F1  
E2F5  
E2F8  
ECT2  
EZH2  
EXO1  
FANCG  
FEN1  
FOXM1 (MPP2) 
GJB2  
HMGB1  
HMGB2  
ING1  
+ + 
+ - 
+ + 
+ + 
+ + 
+ + 
+ + 
+ + 
+ + 
+ + 
+ + 
+ - 
+ + 
+ - 
+ - 
+ + 
+ + 
+ + 
+ + 
+ - 
+ + 
+ + 
+ + 
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KI67 (MKI67)  
KIF2C (MCAK) 
KIF4A  
KIF11 (KNSL1) 
KIF23 (KNSL5) 
KIFC1 (HSET)  
LIG1  
MAD2L1 (MAD2) 
MCM2  
MCM3  
MCM4  
MCM5  
MCM6  
MCM7  
MYC (c-myc)  
NCAPH (XCAP-H) 
NEK2  
ODC1  
ORC1  
PCNA  
PLK1  
PLK4 (Sak-b)  
POLA1  
+ + 
+ + 
+ + 
+ + 
+ + 
+ + 
+ - 
+ + 
+ - 
+ + 
+ + 
+ + 
+ - 
+ + 
+ - 
+ + 
+ + 
+ - 
+ + 
+ + 
+ + 
+ + 
+ + 
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POLD1  
PRC1  
PRIM2 (p58)  
RAD21  
RAD51  
RAD54L  
RPA1  
RPA3  
RRM1  
RRM2  
SLC7A5  
STMN1  
TACC3  
TERT  
TK1  
TMPO (LAP-2) 
TOP2A  
TOPBP1  
TYMS  
SMC2 (SMC2L1) 
SMC4 (SMC2L1) 
SUV39H1   
+ + 
+ + 
+ + 
+ - 
+ + 
+ + 
- - 
- - 
+ + 
- - 
- - 
- + 
- - 
- - 
- + 
+ + 
+ - 
+ - 
+ + 
+ - 
- - 
+ - 
 
Table 1.3 Examples of DREAM and Rb target genes 
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1.3.5 DREAM is functional normally in SW480, and H1299 cell 
lines  
To test whether DREAM or Rb are functioning in the SW480 and H1299 cell 
lines, we performed a luciferase reporter assay. We tested DREAM and RB functions in 
quiescent cells (starved cells) and whether either one of them works or not. In SW480 
serum-starved cells, we did not observe an increase in activity of the ORC1 promoter 
when the E2F binding site is mutated (ORC1 E2F) as compared to the wild-type ORC1 
promoter (ORC1 WT). This might reflect to loss of function of the Rb (Figure 12). In 
contrast, the wild-type ORC1 promoter is repressed compared to ORC1 E2F, suggesting 
that Rb is functional.  A small increase the activity of Bub1 promoter when the CHR 
binding site is mutated (Bub1 CHR) as compared to Bub1 WT suggests that DREAM is 
functional in SW480 and NCI H1299 (Figure 12). 
Taken together, the results of the luciferase assay suggest that Rb is disfunctional 
in SW480, but results for DREAM are ambigous compared to the late cell cycle gene 
expression analysis (Figure 12). 
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Figure 12 The activity of E2F binding sites (Orc1) and CHR binding sites (Bub1) in 
the wild type (WT) (orange) and the serum-starved cells (grey) in the SW480 and 
H1299 cell lines were analyzed by luciferase reporter assay. 
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1.4 Discussion 
Previous studies reported that the Cancer/testis genes (CT) are ectopically 
expressed in various types of human cancers. They are expressed in bladder, lung, 
ovarian, melanoma, and breast tumors [36]. These genes are exclusively expressed in 
male germ cells and placenta [39]. The factors that drive the misexpression of CT genes 
that impacts somatic cells expression and promote the development of cancer remain 
poorly understood. Our study hypothesized that misexpression of CT genes in cancer 
cells is associated with dysfunction of both the transcription suppressors DREAM 
complex and Rb that regulate cell cycle genes through the p53-DREAM pathway. 
The flow cytometry results revealed that serum-starvation induced cancer cells to 
arrest in G0/G1 in respond to limiting growth conditions. Thus, the total percent of the 
cells decreased in S, G2, and M phase indicating that these cell lines arrested in the 
G0/G1 phase and Rb or DREAM function as normal (figure 4A, and 4B), (figure 5A and 
5B), and (figure 6A and 6B). However, the cell lines that were insensitive to serum 
starvation might have a loss of functions of both DREAM and RB (figure 7A, and 7B). 
Furthermore, one of the unexpected results that gene expression analysis of all CT 
genes revealed that they have similar gene expression patterns indicating that we did not 
find a difference in gene expression between cells that can arrest and the cells that cannot 
in limiting growth conditions (figure 8) and (figure 9). Thus, maybe we should test more 
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CT genes to find an appropriate CT with specific expression pattern that is expressed 
only in cancer cells that are lacking both DREAM and Rb and cannot exit cell cycle. 
Moreover, gene expression analysis of early cell cycle genes G0/G1 (MCM5, ORC1, and 
CDC45), and late cell cycle genes G2/M (PBK, BUB1, CCNB2) (figure 10) and (figure 
11) revealed that that either the DREAM or RB is dysfunction in G0/G1. The gene 
expression analysis of late cell cycle genes (CCNB2, PBK, and BUB1) revealed 
unexpected results that suggest that DREAM is dysfunctional in SW480 and H1299 cell 
lines.  
 
Furthermore, to test more directly whether DREAM or Rb is dysfunctional in 
SW480 and H1299, we performed a Luciferase Reporter assay. In contrast to the mRNA 
gene expression results, the results revealed that Rb may be dysfunctional in SW480 cells 
(figure 12). Together, these results do not confirm that loss of DREAM or Rb is linked to 
activation of CT gene expression in human cancer cell lines. 
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1.5 Conclusion 
 
Our study indicates the critical role of DREAM complex in regulating cell cycle 
genes in early cell cycle phases G0, G1 by binding to E2F or E2F and CLE sites, and late 
cell cycle genes G2/M by binding to CHR or CHR and CDE sites. It remains unclear how 
the molecular functions of the DREAM complex differ from Rb. How do they work 
together or overlap to repress cell cycle genes? It is unclear how p53 influences the P53-
DREAM pathway to repress cell cycle in G0/G1 and G2/M or if other unknown genes 
have similar functions to repress or active cell cycle genes. However, in order to test p53 
function, additional studies such as western plot in p53 knockout cells have to be 
conducted. Despite these results, much remains to be learned about how DREAM 
complex and the pocket proteins regulate cell cycle genes through the P53-DREAM 
pathway. In particular, concerning their roles in the soma-to-germline transformation that 
could be associated with cancer development in human mammalian cells.  
 
Although unexpected results, our study may provide an insight into the functions 
of DREAM complex and Rb as transcriptional repressors through the cell cycle genes, 
and how dysfunction of both of them might contribute to promoting tumors development. 
 
 
 
 
58 
1.6 References 
1. Sharma, S., T.K. Kelly, and P.A. Jones, Epigenetics in cancer. Carcinogenesis, 
2010. 31(1): p. 27-36. 
2. Weir, H.K., et al., The past, present, and future of cancer incidence in the United 
States: 1975 through 2020. Cancer, 2015. 121(11): p. 1827-37. 
3. Hanahan, D. and R.A. Weinberg, Hallmarks of cancer: the next generation. Cell, 
2011. 144(5): p. 646-74. 
4. Dick, F.A. and S.M. Rubin, Molecular mechanisms underlying RB protein 
function. Nat Rev Mol Cell Biol, 2013. 14(5): p. 297-306. 
5. Macaluso, M., et al., Modulation of cell cycle components by epigenetic and 
genetic events. Semin Oncol, 2005. 32(5): p. 452-7. 
6. Sadasivam, S. and J.A. DeCaprio, The DREAM complex: master coordinator of 
cell cycle-dependent gene expression. Nat Rev Cancer, 2013. 13(8): p. 585-95. 
7. Engeland, K., Cell cycle arrest through indirect transcriptional repression by 
p53: I have a DREAM. Cell Death Differ, 2018. 25(1): p. 114-132. 
8. Funk, L.C., L.M. Zasadil, and B.A. Weaver, Living in CIN: Mitotic Infidelity and 
Its Consequences for Tumor Promotion and Suppression. Dev Cell, 2016. 39(6): 
p. 638-652. 
9. Scanlan, M.J., A.J. Simpson, and L.J. Old, The cancer/testis genes: review, 
standardization, and commentary. Cancer Immun, 2004. 4: p. 1. 
10. Sever, R. and J.S. Brugge, Signal transduction in cancer. Cold Spring Harb 
Perspect Med, 2015. 5(4). 
11. Hanahan, D. and R.A. Weinberg, The hallmarks of cancer. Cell, 2000. 100(1): p. 
57-70. 
12. Engel, B.E., W.D. Cress, and P.G. Santiago-Cardona, The Retinoblastoma 
Protein: A Master Tumor Suppressor Acts as a Link between Cell Cycle and Cell 
Adhesion. Cell Health Cytoskelet, 2015. 7: p. 1-10. 
13. Egger, J.V., et al., Dephosphorylation of the Retinoblastoma protein (Rb) inhibits 
cancer cell EMT via Zeb. Cancer Biol Ther, 2016. 17(11): p. 1197-1205. 
14. Tower, J., Programmed cell death in aging. Ageing Res Rev, 2015. 23(Pt A): p. 
90-100. 
15. Chen, J., The Cell-Cycle Arrest and Apoptotic Functions of p53 in Tumor 
Initiation and Progression. Cold Spring Harb Perspect Med, 2016. 6(3): p. 
a026104. 
16. Campisi, J., Aging, cellular senescence, and cancer. Annu Rev Physiol, 2013. 75: 
p. 685-705. 
17. Ozaki, T. and A. Nakagawara, Role of p53 in Cell Death and Human Cancers. 
Cancers (Basel), 2011. 3(1): p. 994-1013. 
18. Amin, A., et al., Evasion of anti-growth signaling: A key step in tumorigenesis 
and potential target for treatment and prophylaxis by natural compounds. Semin 
Cancer Biol, 2015. 35 Suppl: p. S55-S77. 
19. Sherr, C.J. and F. McCormick, The RB and p53 pathways in cancer. Cancer Cell, 
2002. 2(2): p. 103-12. 
59 
20. Elmore, S., Apoptosis: a review of programmed cell death. Toxicol Pathol, 2007. 
35(4): p. 495-516. 
21. Igney, F.H. and P.H. Krammer, Death and anti-death: tumour resistance to 
apoptosis. Nat Rev Cancer, 2002. 2(4): p. 277-88. 
22. Campbell, K.J. and S.W.G. Tait, Targeting BCL-2 regulated apoptosis in cancer. 
Open Biol, 2018. 8(5). 
23. Blackburn, E.H. and K. Collins, Telomerase: an RNP enzyme synthesizes DNA. 
Cold Spring Harb Perspect Biol, 2011. 3(5). 
24. Jafri, M.A., et al., Roles of telomeres and telomerase in cancer, and advances in 
telomerase-targeted therapies. Genome Med, 2016. 8(1): p. 69. 
25. Hahn, W.C. and M. Meyerson, Telomerase activation, cellular immortalization 
and cancer. Ann Med, 2001. 33(2): p. 123-9. 
26. Cong, Y.S., W.E. Wright, and J.W. Shay, Human telomerase and its regulation. 
Microbiol Mol Biol Rev, 2002. 66(3): p. 407-25, table of contents. 
27. Akincilar, S.C., B. Unal, and V. Tergaonkar, Reactivation of telomerase in 
cancer. Cell Mol Life Sci, 2016. 73(8): p. 1659-70. 
28. Nishida, N., et al., Angiogenesis in cancer. Vasc Health Risk Manag, 2006. 2(3): 
p. 213-9. 
29. Gasparini, G., et al., Tumor microvessel density, p53 expression, tumor size, and 
peritumoral lymphatic vessel invasion are relevant prognostic markers in node-
negative breast carcinoma. J Clin Oncol, 1994. 12(3): p. 454-66. 
30. Sigismund, S., D. Avanzato, and L. Lanzetti, Emerging functions of the EGFR in 
cancer. Mol Oncol, 2018. 12(1): p. 3-20. 
31. Radinsky, R., et al., Level and function of epidermal growth factor receptor 
predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res, 
1995. 1(1): p. 19-31. 
32. Wells, A., et al., Targeting tumor cell motility as a strategy against invasion and 
metastasis. Trends Pharmacol Sci, 2013. 34(5): p. 283-9. 
33. Xie, K., et al., Cancer-testis antigens in ovarian cancer: implication for 
biomarkers and therapeutic targets. J Ovarian Res, 2019. 12(1): p. 1. 
34. Gurchot, C., The trophoblast theory of cancer (John Beard, 1857-1924) revisited. 
Oncology, 1975. 31(5-6): p. 310-33. 
35. Turco, M.Y., et al., Trophoblast organoids as a model for maternal-fetal 
interactions during human placentation. Nature, 2018. 564(7735): p. 263-267. 
36. Simpson, A.J., et al., Cancer/testis antigens, gametogenesis and cancer. Nat Rev 
Cancer, 2005. 5(8): p. 615-25. 
37. Old, L.J., Cancer/testis (CT) antigens - a new link between gametogenesis and 
cancer. Cancer Immun, 2001. 1: p. 1. 
38. Strome, S. and D. Updike, Specifying and protecting germ cell fate. Nat Rev Mol 
Cell Biol, 2015. 16(7): p. 406-16. 
39. Scanlan, M.J., et al., Cancer/testis antigens: an expanding family of targets for 
cancer immunotherapy. Immunol Rev, 2002. 188: p. 22-32. 
40. Rechtsteiner, A., et al., Repression of Germline Genes in Caenorhabditis elegans 
Somatic Tissues by H3K9 Dimethylation of Their Promoters. Genetics, 2019. 
212(1): p. 125-140. 
60 
41. Ross, M.T., et al., The DNA sequence of the human X chromosome. Nature, 2005.
434(7031): p. 325-37.
42. Hofmann, O., et al., Genome-wide analysis of cancer/testis gene expression. Proc
Natl Acad Sci U S A, 2008. 105(51): p. 20422-7.
43. Caballero, O.L. and Y.T. Chen, Cancer/testis (CT) antigens: potential targets for
immunotherapy. Cancer Sci, 2009. 100(11): p. 2014-21.
44. Yao, J., et al., Tumor subtype-specific cancer-testis antigens as potential
biomarkers and immunotherapeutic targets for cancers. Cancer Immunol Res,
2014. 2(4): p. 371-9.
45. Gjerstorff, M.F., M.H. Andersen, and H.J. Ditzel, Oncogenic cancer/testis
antigens: prime candidates for immunotherapy. Oncotarget, 2015. 6(18): p.
15772-87.
46. Taguchi, A., et al., A search for novel cancer/testis antigens in lung cancer
identifies VCX/Y genes, expanding the repertoire of potential immunotherapeutic
targets. Cancer Res, 2014. 74(17): p. 4694-705.
47. Wu, Y., M. Sarkissyan, and J.V. Vadgama, Epithelial-Mesenchymal Transition
and Breast Cancer. J Clin Med, 2016. 5(2).
48. Wang, D., et al., Somatic misexpression of germline P granules and enhanced
RNA interference in retinoblastoma pathway mutants. Nature, 2005. 436(7050):
p. 593-7.
49. Pothof, J., et al., Identification of genes that protect the C. elegans genome
against mutations by genome-wide RNAi. Genes Dev, 2003. 17(4): p. 443-8.
50. van den Heuvel, S. and N.J. Dyson, Conserved functions of the pRB and E2F
families. Nat Rev Mol Cell Biol, 2008. 9(9): p. 713-24.
51. Cobrinik, D., Pocket proteins and cell cycle control. Oncogene, 2005. 24(17): p.
2796-809.
52. Bertoli, C., J.M. Skotheim, and R.A. de Bruin, Control of cell cycle transcription
during G1 and S phases. Nat Rev Mol Cell Biol, 2013. 14(8): p. 518-28.
53. Wikenheiser-Brokamp, K.A., Retinoblastoma regulatory pathway in lung cancer.
Curr Mol Med, 2006. 6(7): p. 783-93.
54. Liu, H., et al., New roles for the RB tumor suppressor protein. Curr Opin Genet
Dev, 2004. 14(1): p. 55-64.
55. Knudsen, E.S. and J.Y. Wang, Targeting the RB-pathway in cancer therapy. Clin
Cancer Res, 2010. 16(4): p. 1094-9.
56. Narasimha, A.M., et al., Cyclin D activates the Rb tumor suppressor by mono-
phosphorylation. Elife, 2014. 3.
57. Yeo-Teh, N.S.L., Y. Ito, and S. Jha, High-Risk Human Papillomaviral Oncogenes
E6 and E7 Target Key Cellular Pathways to Achieve Oncogenesis. Int J Mol Sci,
2018. 19(6).
58. Litovchick, L., et al., Evolutionarily conserved multisubunit RBL2/p130 and E2F4
protein complex represses human cell cycle-dependent genes in quiescence. Mol
Cell, 2007. 26(4): p. 539-51.
59. Vousden, K.H. and C. Prives, Blinded by the Light: The Growing Complexity of
p53. Cell, 2009. 137(3): p. 413-31.
61 
60. Bohlig, L. and K. Rother, One function--multiple mechanisms: the manifold
activities of p53 as a transcriptional repressor. J Biomed Biotechnol, 2011. 2011:
p. 464916.
61. Soussi, T., et al., Meta-analysis of the p53 mutation database for mutant p53
biological activity reveals a methodologic bias in mutation detection. Clin Cancer
Res, 2006. 12(1): p. 62-9.
62. Weisz, L., M. Oren, and V. Rotter, Transcription regulation by mutant p53.
Oncogene, 2007. 26(15): p. 2202-11.
63. Peart, M.J. and C. Prives, Mutant p53 gain of function: the NF-Y connection.
Cancer Cell, 2006. 10(3): p. 173-4.
64. Wade, M., Y.C. Li, and G.M. Wahl, MDM2, MDMX and p53 in oncogenesis and
cancer therapy. Nat Rev Cancer, 2013. 13(2): p. 83-96.
65. Kruse, J.P. and W. Gu, Modes of p53 regulation. Cell, 2009. 137(4): p. 609-22.
66. Riley, T., et al., Transcriptional control of human p53-regulated genes. Nat Rev
Mol Cell Biol, 2008. 9(5): p. 402-12.
67. Sullivan, K.D., et al., Mechanisms of transcriptional regulation by p53. Cell
Death Differ, 2018. 25(1): p. 133-143.
68. Schmit, F., et al., LINC, a human complex that is related to pRB-containing
complexes in invertebrates regulates the expression of G2/M genes. Cell Cycle,
2007. 6(15): p. 1903-13.
69. Fischer, M., et al., Integration of TP53, DREAM, MMB-FOXM1 and RB-E2F
target gene analyses identifies cell cycle gene regulatory networks. Nucleic Acids
Res, 2016. 44(13): p. 6070-86.
70. Muller, G.A., et al., Timing of transcription during the cell cycle: Protein
complexes binding to E2F, E2F/CLE, CDE/CHR, or CHR promoter elements
define early and late cell cycle gene expression. Oncotarget, 2017. 8(58): p.
97736-97748.
71. Fischer, M. and G.A. Muller, Cell cycle transcription control: DREAM/MuvB and
RB-E2F complexes. Crit Rev Biochem Mol Biol, 2017. 52(6): p. 638-662.
72. Musa, J., et al., MYBL2 (B-Myb): a central regulator of cell proliferation, cell
survival and differentiation involved in tumorigenesis. Cell Death Dis, 2017. 8(6):
p. e2895.
